Endogena Therapeutics embraces a novel therapeutic paradigm of endogenous regenerative medicines using an AI-driven platform to design small molecules.
The CEO and Co-Founder, Matthias Steger, together with an agile and highly experienced team drove the company’s progress from concept to the clinics in 5 years. Furthermore, another strength of Endogena is that we have a strong composition of matter patents.
Pipeline: two advanced projects in ophthalmology
o Lead program EA-2353 in rare disease “Retinitis pigmentosa” in Phase 1/2a, top line results expected in Q4 2023, Orphan Drug Designation granted by FDA Q1 2021
o Second program EA-2351 for Dry Age-Related Macular Degeneration, IND projected Q2 2023
Endogena is applying the regenerative approach beyond ophthalmology to other tissues and diseases, for example in idiopathic pulmonary fibrosis (discovery phase).
The CEO and Co-Founder, Matthias Steger, together with an agile and highly experienced team drove the company’s progress from concept to the clinics in 5 years. Furthermore, another strength of Endogena is that we have a strong composition of matter patents.
Pipeline: two advanced projects in ophthalmology
o Lead program EA-2353 in rare disease “Retinitis pigmentosa” in Phase 1/2a, top line results expected in Q4 2023, Orphan Drug Designation granted by FDA Q1 2021
o Second program EA-2351 for Dry Age-Related Macular Degeneration, IND projected Q2 2023
Endogena is applying the regenerative approach beyond ophthalmology to other tissues and diseases, for example in idiopathic pulmonary fibrosis (discovery phase).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2016
Main Therapeutic Focus:
Ophthalmology
Lead Product in Development:
Retinitis Pigmentosa
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
